CeriBell Positions for 25%-29% Revenue Growth in 2026 Amid 34% Q4 Surge

Medical technology company CeriBell, Inc. (CBLL) has outlined an ambitious growth trajectory for 2026, projecting revenue in the range of $111 million to $115 million—representing 25%-29% expansion from 2025 levels. This forward guidance comes on the heels of a commanding fourth quarter performance that demonstrates the company’s accelerating market momentum and expanding clinical footprint.

Strong Q4 Execution Fuels Full-Year Momentum

The fourth quarter delivered robust results across multiple metrics. Total revenue surged 34% year-over-year to $24.78 million, up from $18.53 million in Q4 2024, with the growth powered by expansion into new customer accounts and intensified adoption within the existing customer base. Breaking this down, product revenue climbed 33% to $18.78 million from $14.15 million, while subscription revenue accelerated 37% to $6.0 million from $4.4 million in the prior-year quarter.

For the full-year 2025, CeriBell’s top-line growth reached 36%, with total revenue climbing to $89.06 million from $65.44 million in 2024. Operating investments expanded to $36.24 million in Q4 (from $29.12 million) and totaled $36.24 million for the full year, reflecting the company’s commitment to scaling operations and supporting product development. On a per-share basis, net losses narrowed meaningfully to $1.46 for full-year 2025, down from $3.39 in 2024, demonstrating improving operational leverage.

The company maintains a solid financial position with $159.3 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

Innovation Pipeline Strengthens Competitive Moat

CeriBell’s growth trajectory is underpinned by a steady stream of FDA clearances that establish the company as a clinical leader in point-of-care electroencephalography (EEG) monitoring. In November 2025, the company secured FDA 510(k) clearance for its Clarity algorithm to detect electrographic seizures in neonates—marking the first and only FDA-cleared seizure detection algorithm across the pre-term neonate through adult population. This clearance enables rapid bedside diagnosis and treatment of non-convulsive seizures, addressing a critical clinical need.

Building on this momentum, CeriBell received additional FDA 510(k) clearance in December 2025 for its proprietary delirium screening and monitoring solution. The delirium monitor analyzes EEG patterns and alerts clinicians to potential delirium, supporting timely evaluation and continuous clinical monitoring.

Most recently, on January 5, 2026, the company earned Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor for hospitalized patients. This designation represents recognition of the solution’s potential to address significant clinical gaps and streamlines the regulatory pathway for commercialization.

Market Opportunity Supports 25%-29% Growth Outlook

The 25%-29% revenue growth projected for 2026 reflects management’s confidence in sustained market penetration across acute care settings. The pipeline of FDA-cleared technologies positions CeriBell to capture share in underserved clinical segments, particularly in seizure detection, delirium monitoring, and stroke management. As hospitals increasingly adopt point-of-care EEG solutions for real-time clinical decision-making, CeriBell’s comprehensive platform and cloud-based EEG portal create stickiness and expansion opportunities within existing accounts.

The stock has traded between $10.01 and $26.04 over the past year, closing at $19.90 in recent trading.